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Abstract
Background—HIV may amplify immunologic, physiologic, and functional changes of aging. 
We determined associations of frailty phenotype, a T-cell senescence marker (p16INK4a 
expression), age, and demographics with exposures of the intracellular metabolites (IM) and 
endogenous nucleotides (EN) of tenofovir/emtricitabine (TFV/FTC), efavirenz (EFV), atazanavir 
(ATV), and ritonavir (RTV).
Materials and Methods—Plasma and PBMC samples for drug, IM, and EN concentrations 
were collected at 4 time points in HIV+ adults receiving TFV/FTC with EFV or ATV/RTV. 
Subjects underwent frailty phenotyping and p16INK4a expression analysis. Noncompartmental 
analysis generated an area under the curve (AUC) for each analyte. Spearman rank correlation and 
Kruskal-Wallis tests were used to assess associations between AUC, demographics, and aging 
markers, adjusting for multiple comparisons with the Holm procedure.
Results—Subjects (n=79) ranged in age from 22–73yr (median 48yr). Forty-eight were African-
American, 24 were female, 54 received EFV. Three subjects (range 51–60yr) demonstrated frailty, 
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with 17 subjects (range 26–60yr) demonstrating pre-frailty. Negative associations were observed 
between p16INK4a expression and each of FTC-triphosphate (r= −0.45), deoxyadenosine 
triphosphate (dATP) (r= −0.47), and deoxycytidine triphosphate (dCTP) (r= −0.57) AUCs (p-
values<0.02). TFV and FTC AUCs were larger among subjects with lower renal function or higher 
chronologic age (p-values ≤0.05). No associations were observed for EFV, ATV, or RTV AUCs.
Conclusions—Associations of IM/EN exposure and p16INK4a expression observed here suggest 
that senescence may alter drug phosphorylation, metabolism, or transport. This finding warrants 
further mechanistic study to ensure optimal treatment in the aging HIV+ population.
Introduction
Older HIV-infected adults (≥50 years) may experience increased morbidity/mortality due to 
overlapping effects of HIV infection and aging.(1, 2) Optimal antiretroviral (ARV) therapy 
is critical to the health of this growing HIV sub-population. Despite this, little is known 
regarding how the physiologic and immunologic processes of aging may affect ARV 
pharmacokinetics. As cohort studies demonstrate, chronologic age is an imperfect marker of 
aging, particularly in HIV-infected subjects, (3, 4) and measuring other biomarkers of aging, 
such as frailty and cellular senescence, should be undertaken.
Nucleoside reverse transcriptase inhibitors (NRTIs), particularly tenofovir (TFV) and 
emtricitabine (FTC), form the backbone of recommend ARV regimens,(5) and undergo 
metabolism in immune cells to their active phosphorylated forms.(6) These intracellular 
metabolites (IM) compete with endogenous nucleotides (EN) during reverse transcription. 
The IM:EN ratio may be important for virologic efficacy,(7, 8) although little is known 
about the concentrations of EN in HIV-infected patients receiving ARVs, or effects of 
cellular senescence on IM/EN concentrations.
Here, we present the results of ARV, IM, and EN area under the curve (AUC; a measure of 
exposure) in HIV-infected subjects, and their associations with aging biomarkers.
Methods
Clinical Study Conduct
HIV-infected adults (≥18 years) receiving TFV/FTC 300/200mg with efavirenz 600mg 
(EFV) or atazanavir/ritonavir 300/100mg (ATV/r) daily for ≥two weeks were recruited from 
the UNC HealthCare Infectious Diseases Clinic (Chapel Hill, NC) and the Cone Health 
Regional Center for Infectious Diseases (Greensboro, NC). The study protocol was approved 
by the Institutional Review Boards of both institutions (Clinicaltrials.gov NCT01180075).
Subjects underwent eligibility screening prior to providing 4 timed blood samples (pre-dose, 
and 2, 4–6, and 10–14 hours post-dose). Sampling times were optimized based on a previous 
intensive PK study in older HIV-infected adults.(9) Subjects completed the protocol in 1–3 
visits, providing 1–2 blood samples per visit; subjects underwent frailty phenotyping and 
provided blood for p16INK4a analysis once.
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Subjects were included in the study if they: demonstrated adherence, defined as ≤1 missed 
dose in the last week and no missed doses in the 3 days prior to sampling; were not anemic 
(hemoglobin <10 mg/dL); were not receiving co-medications expected to alter ARV drug 
exposures by ≥30% or alter intracellular nucleotide pools; had no unstable, acute, medical 
conditions, and no DAIDS Grade ≥2 lab abnormalities, with the exception of total bilirubin 
for subjects receiving ATV/r. Subjects were included if their creatinine clearance (CrCL), as 
calculated by the Cockroft-Gault formula,(10) was >30 mL/min. Women of childbearing 
potential underwent urine pregnancy testing prior to sampling, as pregnancy was 
exclusionary.
Frailty phenotyping was conducted per Fried et al(11). Three positive markers of the frailty 
phenotype defined frailty, while 1–2 positive markers defined pre-frailty. Testing was 
conducted by the NC TraCS Institute Bionutrition Core.
Analytical Methods
Blood collected in K2EDTA tubes was kept on ice and centrifuged at 3000g for 15 minutes 
at 4C within 30 minutes of collection to recover plasma, and stored at −80C until analysis. 
Total concentrations of TFV, FTC, EFV, ATV, and ritonavir (RTV) were analyzed using 
validated methods.(12, 13) Additional File 1 contains brief methods for unbound EFV, ATV, 
and RTV concentrations.
Blood collected in 8mL CPT tubes was stored at room temperature for ≤4 hours prior to 
centrifugation. Internal testing demonstrated that samples could undergo centrifugation at 
1300g for 30 minutes, the resulting cell layer and plasma transferred to a 15mL conical tube, 
and stored on ice for ≤8 hours from collection without significant decreases in cell count or 
drug concentrations (data not shown). Samples were then processed to recover peripheral 
blood mononuclear cells (PBMCs) for IM and EN concentrations, as previously described.
(9) Brief methods of the tenofovir diphosphate (TFV-dp), emtricitabine triphosphate (FTC-
tp), deoxyadenosine triphosphate (dATP), and deoxycytidine triphosphate (dCTP) assay are 
provided in Additional File 1. Drug concentrations were determined in the UNC Center for 
AIDS Research Clinical Pharmacology and Analytical Chemistry Laboratory.
Blood collected in K2EDTA tubes was used to isolate T-cells and provide cellular RNA for 
PCR-based determination of p16INK4a expression, using previously published methods.(14)
Pharmacokinetic and Statistical Analysis
Subjects who completed the study per protocol were included. To construct an AUC, the 
four samples were assumed to occur in the same dosing interval. Pre-dose samples were 
assigned to the end, rather than the beginning, of the dosing interval to capture exposure 
from 2–24 hours. Phoenix Win Nonlin 6.3 (Pharsight, A Certara Company, St. Louis, MO) 
was used to calculate AUC, using the linear up/log down method and oral dosing model. 
Exact Wilcoxon rank-sum tests were used to test the IM and EN AUCs for differences 
between regimens.
Associations between AUC and subject demographics, including positive frailty 
components, CD4:CD8 ratio and p16INK4a expression, were assessed using Spearman’s rank 
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correlation test (continuous variables) and an exact Kruskal-Wallis test (categorical 
variables). Because age and CrCL were significantly correlated, multiple linear regression of 
AUC was used to assess adjusted associations for these variables. For statistical analyses, 
AUC values were log10-transformed and p16INK4a values were log2-transformed. A two-
sided p-value ≤0.05 was considered statistically significant; the Holm (stepdown Bonferroni) 
procedure was used to adjust for multiple comparisons (174 tests); reported p-values are the 
Holm-adjusted values unless otherwise noted. Analyses were conducted in SAS version 9.4 
(SAS Institute, Cary, NC) or R 3.1.2 (r-project.org).
Results
Subject Demographics and Safety
Fifty-four subjects receiving TFV/FTC/EFV and twenty-five receiving TFV/FTC/ATV/r 
were enrolled and provided ≥1 blood sample. Subject demographics are provided in Table 1. 
Seventy-three of 79 subjects completed the study per protocol; the remaining 6 did not 
provide 4 blood samples and were excluded. Three subjects demonstrated frailty; 1 receiving 
TFV/FTC/ATV/r and 2 receiving TFV/FTC/EFV. No serious adverse events were reported. 
Concentration-time plots are provided in Additional File 2.
Associations of Exposure with Aging Markers and Demographics
Results of the Spearman correlation analyses are presented in Table 2. No statistically 
significant differences were observed for the IM/EN AUCs between regimens (unadjusted 
p>0.1); all association testing was done using pooled AUCs. Figure 1a–h shows scatter plots 
of IM/EN AUCs vs. demographics shown in Table 2.
Age and CrCL were significantly associated with FTC and TFV AUC, with the Spearman 
rho (r) demonstrating relationships of similar strength, but in opposite direction, i.e., a 
positive association between AUC and age (r= 0.54, 0.49 for FTC and TFV, respectively), 
and a negative association between AUC and CrCL (r= −0.56, −0.57 for FTC and TFV, 
respectively). Age remained significantly associated with TFV AUC and FTC AUC after 
adjusting for CrCL, and vice versa (p<0.05).
Negative associations between p16INK4a and AUC were observed for FTC-tp, dATP, and 
dCTP (r= −0.45, −0.47, −0.57, p= 0.018, 0.007, and <0.001, respectively).
After adjustment for multiple comparisons, no significant associations between EFV, ATV, 
and RTV total or unbound AUCs with any of the tested demographics, including frailty and 
p16INK4a expression, were observed (not shown).
Discussion
In this study, an association between increasing age/decreasing CrCL and TFV/FTC 
exposures, and an association of higher p16INK4a expression and lower intracellular 
exposures of FTC-tp, dATP, and dCTP were observed. The association between CrCL and 
TFV/FTC AUC is expected (15), however, the association with chronologic age remained 
significant after controlling for CrCL. The negative associations between p16INK4a 
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expression and FTC-TP and ENs were unexpected, and may suggest senescence-altered 
cellular transport of nucleotides, and/or alterations of kinase/phosphorylase activity involved 
in their metabolism. Inflammation, part of the senescent-cell phenotype, may affect hepatic 
drug metabolizing enzymes,(16) and could affect enzyme function at other sites, such as in 
PBMCs.(17) The drugs themselves may alter p16INK4a expression; aging patients and/or 
patients with persistent immune activation may possess different cellular subpopulations 
within PBMC samples, affecting apparent phosphorylation. The clinical implications and 
mechanisms of these findings remain to be elucidated.
Several investigations have suggested that TFV/TFV-dp concentrations are increased in 
subjects receiving protease-inhibitors, likely due P-glycoprotein inhibition in PBMCs.(18, 
19) However, we and others (20) have not observed this in our data.
Strengths of this work include measuring parent, IM, and EN concentrations for TFV/FTC, 
and total/unbound EFV, ATV, and RTV concentrations in 73 HIV-infected adults, along with 
measuring frailty and senescence markers. Limitations include the small number of frail 
subjects, and a moderate sample size relative to the number of hypothesis tests. Nonetheless, 
this work provides a basis for further investigation of intracellular pharmacology and effects 
of senescence on NRTI metabolism, efficacy, and toxicity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1a–h. 
Scatter plots of tenofovir disphosphate (TFV-tp), emtricitabine triphosphate (FTC-tp), 
deoxyadenosine triphosphate (dATP), and deoxycytidine triphosphate (dCTP) area under the 
curve (AUC) values vs. log2p16INK4a (log2p16) expression (a–d); TFV and FTC AUC 
values vs. age (e, f); and TFV and FTC AUC values vs. creatinine clearance (CrCL; g,h), by 
regimen. Subjects receiving TFV/FTC with efavirenz are shown in the open circles; those 
receiving TFV/FTC with atazanavir/ritonavir are shown in the closed circles.
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Table 1
Demographic data of study subjects. Data are presented as median (min, max) or number (percent). BMI: 
body mass index; CrCL: creatinine clearance.
Characteristic Total (n=79) Efavirenz Group (n=54) Atazanavir/ritonavir Group (n=25)
Age (years) 48 (22, 73) 48 (22, 73) 48 (24, 61)
HIV Duration (years) 10 (1, 31) 10 (1, 31) 11 (1, 24)
BMI (kg/m2) 28.1 (17.6, 44.3) 27.1 (17.6, 44.3) 29.8 (20.2, 40.4)
CrCL (mL/min) 108 (43, 228) 109 (43, 200) 100 (67, 228)
Log2(p16INK4a) 2.03 (−1.1, 3.91) 1.93 (−1.14, 2.81) 2.23 (0.16, 3.91)
CD4 Count (cell/mm3) 732 (125, 1724) 736 (126, 1724) 692 (375, 1436)
CD4:CD8 ratio 0.9 (0.3, 2.8) 0.9 (0.3, 2.8) 0.9 (0.3, 1.4)
Female 24 (30%) 14 (26%) 10 (40%)
Race
African American 48 (61%) 32 (59%) 16 (64%)
Caucasian 26 (33%) 19 (35%) 7 (28%)
Other/Unknown 5 (6%) 3 (6%) 2 (8%)
Total Frailty Markers n=75 n=50 n=25
0 55 (73%) 40 (80%) 15 (60%)
1–2 (pre-frail) 17 (23%) 8 (16%) 9 (36%)
3 (frail) 3 (4%) 2 (4%) 1 (4%)
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Table 2
Spearman rho (r) and Holm adjusted p-values for associations between demographic variables and analyte area 
under the curve (AUC), with the number of subjects who completed per protocol. CrCL: creatinine clearance; 
dATP: deoxyadenosine triphosphate; dCTP: deoxycytidine triphosphate; TFV-dp: tenofovir diphosphate; FTC-
tp: emtricitabine triphosphate; TFV: tenofovir; FTC: emtricitabine.
Analyte AUC tested
Age
r (adjusted p-value)
n=73
Calculated CrCL
r (adjusted p-value)
n=73
Log2 p16INK4a
r (adjusted p-value)
n=70
dATP −0.09 (1) −0.06 (1) −0.47 (0.0066)
dCTP −0.14 (1) 0.17 (1) −0.57 (<0.0001)
TFV-dp 0.23 (1) −0.26 (1) −0.33 (0.8105)
FTC-tp 0.02 (1) −0.009 (1) −0.45 (0.0179)
TFV 0.49 (0.0017) −0.57 (<0.0001) 0.047 (1)
FTC 0.54 (<0.0001) −0.56 (0.0001) 0.36 (0.4302)
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